You Don’t Need Awards to Raise VC — You Need These 2 Things

Founders in the longevity and healthspan space often ask whether awards are necessary to be taken seriously by investors. It’s understandable. When a sector is crowded and narratives move faster than evidence, recognition starts to feel like validation or a shortcut to credibility in a system that doesn’t always reward patience.

But as an investor focused on extending healthy human life, I’ve found the opposite to be true. Awards may be encouraging and occasionally useful for visibility, but they are weak indicators of validation and poor predictors of long-term success. In the longevity and healthspan industry, where timelines are long and claims are easy to overstate, venture capital ultimately follows alignment and evidence, not applause received at glitzy industry events.

Sign up for the Entrepreneur Daily newsletter to get the news and resources you need to know today to help you run your business better. Get it in your inbox.

Recognition isn’t the same as validation

The distinction that matters is between recognition and real validation. Awards tend to reflect how compelling a story is at a moment in time — what judges perceive based on limited information — rather than how durable a business actually is. Research on business plan competitions and awards emphasizes this gap. A systematic review of business plan competitions shows a fragmented literature with exploratory findings and highlights a lack of rigorous evidence linking competition outcomes to firm performance or survival.

Another study conducted by The World Bank Group comparing predictive models for startup outcomes found that even structured forecast approaches struggle to predict success, underscoring that intuitive or judged signals, like competition wins, are not reliable predictors of future performance.

These research strands together suggest that winning prizes doesn’t automatically translate into sustained growth; the deeper drivers of success lie elsewhere.

Why this gap matters more in longevity

This gap is even more visible in the rapidly rising longevity economy, which Swiss bank UBS predicted to be worth $8 trillion by 2030. Healthspan companies operate in a domain where the consequences of being wrong are real, where biological systems resist simplification and where translation from insight to intervention is the work. In this context, validation is not a logo or a prize, but a growing body of evidence that compounds over time.uu

A plausible mechanism grounded in established biology is only the beginning. What follows are: reproducibility of results, thoughtful biomarker strategy, regulatory realism and a credible path to outcomes that matter to patients, clinicians and consumers. These are far more indicative of long-term potential. None of this fits neatly into an awards submission, and that is precisely the point.

Awards help, but they’re not the reason to apply

Founders also often misread the order in which things happen. Some of the companies I’ve invested in had already received industry awards, but those were not the reason they were funded. What mattered was the underlying execution. What mattered to me was how rigorously they were testing assumptions, how honestly they handled data and whether the team understood both the potential and the limits of what they were building.

Awards were a lagging indicator of momentum that already existed in the fundamentals: disciplined experimentation, intellectual honesty, speed of learning and teams that understood both the promise and the limits of their approach. This experience does not make me anti-awards; it makes me cautious about confusing correlation with causation.

What “impact alignment” actually means

What actually drives investment decisions is alignment, and in longevity, that word needs to be taken seriously. Alignment is not about sharing enthusiasm for longer lives for the sake of it. It is about agreeing on what impact means in concrete terms.

Impact, in this context, is not a feel-good narrative; it’s a measurable one, even if more qualitatively than quantitatively in some cases. For me, it’s about which healthspan outcome is being targeted, for whom and why? How will progress be measured with replicable methods? What would count as failure? What tradeoffs are acceptable, and which ones are not? When founders and investors are aligned on these questions, capital becomes a tool for building evidence rather than amplifying narrative.

When they are not, no amount of external validation can compensate. Misalignment shows up later as pressure to overstate results, to rush translation or to prioritize press cycles over scientific integrity. And my ultimate concern is that awards do nothing to prevent these pitfalls or even predict them in the first place.

The quiet signal investors notice

There is also a quieter signal that investors notice, but founders rarely consider. Many of the most credible teams in healthspan are simply too busy doing the work to chase recognition. They are running studies, refining protocols, negotiating partnerships and confronting inconvenient data. The absence of awards often reflects focus more than a lack of ambition.

A better question for founders to ask

For founders seeking funding, the more useful question is not how to win recognition, but how to build trust. What would make a skeptical scientist take the work seriously? What would make a clinician believe it belongs in practice? What would make outcomes measurably better at scale? These are the questions that shape conviction in longevity investing, even if they are less glamorous than a trophy.

The long view

Awards may help open a conversation, but just be aware that they rarely sustain one or even ensure further collaborations. In healthspan, the companies that endure will be those whose proof compounds, whose claims narrow rather than inflate over time and whose definition of impact is shared by the investors they choose as partners.

You do not need awards to raise venture capital. You do need alignment, rigor and the patience to let evidence speak. Recognition may arrive along the way. If it does, enjoy it. Just do not mistake it for validation.

Sign up for Entrepreneur’s Franchise Bootcamp, a free, 5-day email course on how to find and invest in your first profitable franchise — no business experience required.

Founders in the longevity and healthspan space often ask whether awards are necessary to be taken seriously by investors. It’s understandable. When a sector is crowded and narratives move faster than evidence, recognition starts to feel like validation or a shortcut to credibility in a system that doesn’t always reward patience.

But as an investor focused on extending healthy human life, I’ve found the opposite to be true. Awards may be encouraging and occasionally useful for visibility, but they are weak indicators of validation and poor predictors of long-term success. In the longevity and healthspan industry, where timelines are long and claims are easy to overstate, venture capital ultimately follows alignment and evidence, not applause received at glitzy industry events.